Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, discusses the impact of prior therapies, including blinatumomab, on the outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with CAR-T therapy. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.